Document:

<PAGE>

                                 [LOGO] DIOMED

                                                                   Exhibit 10.11

                     EVLT MARKETING AND PROMOTION AGREEMENT

             EVLT Marketing and Promotion Agreement entered into as of August
      29, 2001 between Diomed, Inc., a Delaware corporation having its principal
      offices at 1 Dundee Park, Andover, MA 01810 ("Diomed"), Dr. Steven E.
      Zimmet of Austin, Texas (the "Doctor"), and Endovenous Associates, L.P., a
      Texas limited partnership with a principal office at 1801 N. Lamar Blvd.,
      Suite 103, Austin, Texas 78701 (the "LP").

     RECITALS

             WHEREAS, Diomed is in the business of developing, marketing,
      manufacturing and selling laser systems for medical applications;

             WHEREAS, Diomed has filed a patent application covering design and
     function of optical fibers, application number 85.70.75122 15 June 2001,
     entitled medical laser device (such patent application, together with all
     inventions, discoveries or improvements authored, conceived, developed,
     reduced to practice, or otherwise obtained by the Doctor that are
     referenced thereinor relate thereto are referred to collectively as the
     "Fiber Patent").

             WHEREAS, the Doctor is trained and knowledgeable in the use of
     lasers for the Endovenous treatment of varicose veins ("EVLT") (EVLT is a
     Diomed Trademark);

             WHEREAS, the Doctor has formed a single member LP for the purpose
     of conducting the activities contemplated by this Agreement;

             WHEREAS, Diomed desires to market and sell lasers worldwide for use
     in EVLT and is in the process of obtaining FDA approval for the use of its
     lasers to perform EVLT;

             WHEREAS, the Doctor, acting through the LP, is willing to train
     other physicians in the use of the Diomed laser for EVLT and is otherwise
     willing to promote the use of the Diomed laser for EVLT all as more
     specifically set forth in this Agreement;

             WHEREAS, Diomed wishes to engage the Doctor, acting through his LP,
     to help maximize Diomed's sales worldwide of lasers for EVLT and the Doctor
     and the LP, wish to provide assistance to Diomed in connection with the
     marketing and promotion of the lasers for EVLT, all on the terms and
     conditions herein set forth;

             WHEREAS, For the purpose of this contract EVLT is defined as any
     internal Varicose Vein Treatment performed with a laser and a optical
     fiber;

              NOW, THEREFORE, the parties hereby agree as follows:

     I.       MARKETING OBLIGATIONS OF THE PARTIES

              1.1     Covenant to Promote the Product for EVLT. Subject to the
                      terms and conditions of this Agreement, Diomed, the Doctor
                      and the LP shall work together and use their respective
                      best efforts to promote the use of the Diomed lasers for
                      EVLT throughout the world during the Term (as hereinafter
                      defined).

Diomed, Inc. One Dundee Park, Suites 5&6, PO Box 97, Andover MA 01810 USA
Tel: +1 978 475 7771

Fax: +1 978 475 8488     a    Email: diomed@diomed-lasers.com
http://www.diomed-lasers.com

UK: Diomed Limited. Cambridge Research Park, Ely Road, Cambridge CB5 9TE,
United Kingdom       a        Tel:+44 1223 729300        Fax:+44 1223 729329
Email: info@diomed-lasers.com

<PAGE>
                                 [LOGO] DIOMED

              1.2     Exclusive Promotion. The Doctor and the LP each agrees
                      that, during the Term (and thereafter as provided in
                      Section 5.7), he and it shall not actively promote to
                      third parties any product for EVLT other than Diomed
                      lasers, optical fibers and associated EVLT kits.

              1.3     Proprietary Rights.

                      1.3.1   The Doctor hereby assigns, grants, conveys and
                              transfers to Diomed any and all right, title and
                              interest he has or may have in and to the Fiber
                              Patent. The Doctor will from time to time execute
                              and deliver to Diomed such documentation and take
                              such other reasonable action, at Diomed's expense,
                              which Diomed may request in order to effectively
                              carry out this Section and invest in Diomed the
                              Fiber Patent and title thereto. The Doctor will
                              assist Diomed in every proper way (but at Diomed's
                              expense) to obtain and from time to time enforce
                              rights with respect to the Fiber Patent in any and
                              all countries, and will execute all documents
                              reasonably necessary or appropriate for this
                              purpose. In the event that Diomed is unable for
                              any reason whatsoever to secure the Doctor's
                              consent to any document reasonably necessary or
                              appropriate for any of the foregoing purposes,
                              (including renewals, extensions, continuations,
                              divisions or continuations in part), the Doctor
                              hereby irrevocably designate and appoint Diomed
                              and its duly authorized officers and agents, as
                              his agents and attorneys in fact to act for and on
                              his behalf and instead of him, for the purpose of
                              executing and filing any such document and doing
                              all other lawfully permitted acts to accomplish
                              the foregoing purposes with the same legal force
                              and effect as if executed by him.

                      1.3.2   The Doctor and LP hereby acknowledge that "EVLT"
                              is a trademark of Diomed, and that neither the
                              Doctor nor the LP has any rights therein. The
                              Doctor and the LP understand that Diomed intends
                              to register such trademark with the U.S. Patent
                              and Trademark Office, and agree to reasonably
                              cooperate with Diomed so as to permit Diomed to
                              obtain such registration.

         II.   Duties of The Doctor

               Subject to the terms and conditions of this Agreement, during the
               Term:

               2.1      EVLT Training of Other Physicians. The Doctor, acting
                        through the LP, agrees to use his best efforts to
                        personally train other qualified physicians, as set
                        forth in Exhibit B, and identified and approved by the
                        President or the Director of Marketing of Diomed in the
                        use of Diomed lasers for EVLT. The Doctor will provide
                        Diomed with a certification in the form attached hereto
                        as Exhibit A when each physician's training is complete.

                            2.2      Promotional Activities. The Doctor, acting
                                     through his LP, will use his best efforts
                                     to perform the promotional activities set
                                     forth in Exhibit B, as Exhibit B may be
                                     amended from time to time by written
                                     consent of Diomed and the Doctor.

<PAGE>
                                 [LOGO] DIOMED

     2.3     Confidentiality. The Doctor and the LP each acknowledge that
             information about Product sales to be provided by Diomed to the
             Doctor and the LP hereunder and any other information provided to
             the Doctor or the LP and designated as confidential by Diomed at
             the time of disclosure constitute confidential and proprietary
             information of Diomed and the Doctor and the LP each agree that he
             and it will not use such information except in furtherance of the
             purposes of this Agreement and will hold such information in strict
             confidence. The obligations of the Doctor and the LP under this
             Section 2.3 shall be limited to a period of three years from the
             date of expiration or earlier termination of this Agreement.
             Neither the Doctor nor the LP shall have any obligation of
             confidentiality with respect to any information (a) in the public
             domain, other than by a breach of this Section 2.3 by either of
             them, (b) rightfully received from a third party without any
             obligation of confidentiality, or (c) generally made available to
             third parties by Diomed without restriction on disclosure.

     2.4     Personal Obligation. Notwithstanding the Doctor's use of the LP to
             provide services under this Agreement, all obligations of the
             Doctor and the LP under this Agreement shall be joint and several
             and such obligations may be fully enforced by Diomed against either
             the Doctor or the LP should the other party breach this Agreement.
             Notwithstanding anything to the contrary contained in this
             Agreement, in no event shall the total liability of the Doctor
             and/or the LP for damages arising out of this Agreement exceed the
             aggregate amount of consideration received by the Doctor and/or the
             LP (whether in cash, or exercised options or shares of capital
             stock) under this Agreement (it being understood that such
             limitation on liability for damages shall not limit Diomed's
             ability to seek injunctive or other equitable relief against either
             the Doctor or the LP in the event the Doctor breaches his
             obligations under Sections 1.2, 1.3, or 2.3).

III.  Obligations of Diomed

      Subject to the terms and conditions of this Agreement, during the Term
      Diomed agrees as follows:

3.1   Initial Payment. With in 60 days of execution of this Agreement, Diomed
      will pay the LP the sum of **CONFIDENTIAL TREATMENT REQUESTED**.

3.2   Payment for Training. Within thirty (30) days of receipt of certification
      in the form of Exhibit A from the Doctor that training of physicians
      pursuant to Section 2.1 has been completed, Diomed will pay the LP
      **CONFIDENTIAL TREATMENT REQUESTED** for each such approved training
      session per licensed physician. Within thirty (30) days of submission of
      receipts, Diomed will reimburse up to **CONFIDENTIAL TREATMENT REQUESTED**
      for foreign travel and **CONFIDENTIAL TREATMENT REQUESTED** for domestic
      travel for pre-approved lectures/workshops where discussion or
      presentation on EVLT is on the agenda.

3.3   Payments Based on Product Sales.

      3.3.1 From the Effective Date until termination of this Agreement (by
            expiration or earlier termination) or until total payments hereunder
            reach **CONFIDENTIAL TREATMENT REQUESTED** whichever first occurs,
            and except as described in Section 3.3.2 below, Diomed

<PAGE>
                                 [LOGO] DIOMED

            will pay the LP **CONFIDENTIAL TREATMENT REQUESTED** for each
            Product (as hereinafter defined, and other than OEM Sales) sold in
            North America (defined as Canada and the United States) and
            **CONFIDENTIAL TREATMENT REQUESTED** for each Product (other than
            OEM Sales) sold in the rest of the world. Payment shall be made
            within thirty (30) days of the end of each calendar quarter
            following the Effective Date. In the case of OEM Sales (as defined
            below), Diomed will pay to the LP **CONFIDENTIAL TREATMENT
            REQUESTED** for each Product sold in North America and
            **CONFIDENTIAL TREATMENT REQUESTED** for each Product sold in the
            rest of the world. An "OEM Sale" shall mean any sale of a Product to
            a purchaser under an agreement where the Product is delivered
            without a Diomed logo and the purchaser has the rights to separately
            brand the Product. Reductions shall be allowed for returned Products
            and uncollected accounts. Each payment will be accompanied by a
            report as set forth in Section 3.8.

      3.3.2 Notwithstanding the payments provided under Section 3.3.1 above, the
            parties agree that Diomed may reduce such specified payments should
            Diomed earn an overall Gross Margin on the Products of less that
            **CONFIDENTIAL TREATMENT REQUESTED**. Should on a quarterly basis,
            Diomed's Gross Margin fall below **CONFIDENTIAL TREATMENT
            REQUESTED** then the payments specified in Section 3.3.1 above shall
            be adjusted as follows:

        -   **CONFIDENTIAL TREATMENT REQUESTED** reduction when Gross Margin is
            below **CONFIDENTIAL TREATMENT REQUESTED** but above **CONFIDENTIAL
            TREATMENT REQUESTED**

        -   **CONFIDENTIAL TREATMENT REQUESTED** reduction when Gross Margin is
            below **CONFIDENTIAL TREATMENT REQUESTED** but above **CONFIDENTIAL
            TREATMENT REQUESTED**

        -   **CONFIDENTIAL TREATMENT REQUESTED** reduction when Gross Margin is
            below **CONFIDENTIAL TREATMENT REQUESTED** but above **CONFIDENTIAL
            TREATMENT REQUESTED**

        -   **CONFIDENTIAL TREATMENT REQUESTED** reduction when Gross Margin is
            below **CONFIDENTIAL TREATMENT REQUESTED** but above **CONFIDENTIAL
            TREATMENT REQUESTED**

        -   **CONFIDENTIAL TREATMENT REQUESTED** reduction when Gross Margin is
            below **CONFIDENTIAL TREATMENT REQUESTED** but above **CONFIDENTIAL
            TREATMENT REQUESTED**

        -   **CONFIDENTIAL TREATMENT REQUESTED** reduction when Gross Margin is
            below **CONFIDENTIAL TREATMENT REQUESTED**

            In no case shall the reduction exceed **CONFIDENTIAL TREATMENT
            REQUESTED**. For purposes of this Section, Gross Margin shall be
            determined quarterly under generally accepted accounting principles
            in the United States, with the payments under this Agreement
            included in cost of sales. The Gross Margin shall be computed to two
            places (e.g., ".48") with fractions of one half or less rounded down
            and fractions greater than one half rounded up. For example the
            number 49.55% would be rounded up to 50%. Should a reduction under
            this Section apply in any quarter, Diomed will provide documentation
            for the reduction and the LP may request that Diomed's independent
            auditors (at Diomed's expense) and as part of the annual audit,
            certify such computation. Such a request must be made in writing
            within 45 days of year end.

      3.3.3 In addition to payments for Products as provided for above, Diomed
            shall pay the LP **CONFIDENTIAL TREATMENT REQUESTED** for each
            optical fiber manufactured and sold by Diomed utilizing the unique
            fiber design components of the Fiber Patent (a "Qualified Fiber").
            Where a Qualified Fiber is included in a disposable Kit which
            contains other

<PAGE>
                                 [LOGO] DIOMED

      components the amount paid shall be **CONFIDENTIAL TREATMENT REQUESTED**
      for each kit which includes a Qualified Fiber.

3.4   Certain Definitions. For purposes of this Agreement, "Product" or
      "Products" means the Diomed D15 plus and D30 plus lasers (and equivalents)
      that are sold with an EVLT application box and excludes all fibers,
      disposables and related services.

3.5   Initial Option Grant. In consideration of the undertakings by the Doctor
      and the LP herein, Diomed hereby grants to the LP an option (the "Initial
      Option") to purchase 30,000 shares of Diomed Common Stock at a purchase
      price of $2.25 per share under the 2001 Stock Option Plan adopted by
      Diomed (the "Plan"). The Initial Option shall be fully vested on issuance
      and exercisable for a period of two (2) years from the date of grant. The
      Initial Option will be non transferable and may only be exercised on the
      condition that the Doctor executes the Stockholder Agreement attached
      herewith as Exhibit C (as it may be amended from time to time). The
      Initial Option (and shares issued on exercise thereof) shall also be
      subject to all provisions of the Certificate of Incorporation and Bylaws
      of Diomed, or successor entity, as from time to time revised or amended or
      terms of any conversion of the options in connection with a merger or
      acquisition with another company so long as the holder is treated on a
      pari parsu basis.

 3.6  Product Options. For each Product sold by Diomed beginning on the
      Effective Date and ending November 15, 2005, Diomed will grant to the LP
      under the Plan an option (a "Product Option") to purchase five (5) shares
      of Common Stock of Diomed up to an aggregate maximum of 45,000 shares
      (which number is inclusive of shares subject to options granted under
      Section 3.5). The Product Options shall be granted as of the end of each
      calendar quarter in which Product sales were sold (subject to adjustment
      for returns and uncollected accounts) and shall be fully vested on grant.
      The Product Options issued hereunder shall be subject to the same terms as
      the Initial Options issued under Section 3.5 except that the exercise
      price of each quarterly grant shall be based on fair market value of
      Diomed common stock at the time of grant as determined at the sole
      discretion of the Board of Director and consistent with other Employee
      options (if any) granted during the quarter.

 3.7  Quarterly Report. Diomed shall provide the Doctor with a report within
      thirty (35) days of the end of each calendar quarter specifying the number
      of Products sold for EVLT during the immediately prior calendar quarter
      (and specifying sales in North America and sales in the rest of the
      world), the number of stock options earned as a result of such sales, the
      exercise price of the stock options, and the aggregate number of stock
      options awarded the LP to the date of the report. For purposes of the
      Product Options, the number of Products sold in any given quarter shall
      equal the number of Products for which Diomed is obligated to make a
      payment under Section 3.3.

      3.8     Annual Verification. Within ninety (90) days of the close of each
              calendar year, Diomed will provide the Doctor with an annual
              report of the number of Products sold in the immediately preceding
              calendar year, verified by Diomed's auditors. The Doctor and/or
              the LP shall have the right to audit Diomed's books and records
              related to the transactions contemplated under this Agreement. In
              addition to any other sums that may be owing to the Doctor and/or
              the LP as a result of such audit, Diomed shall be responsible for
              the cost of such audit in the event a discrepancy of five percent
              (5%) of more is documented by the Doctor's and/or LP's auditor.

4     Investment Representations

      4.1   Option Grants Subject to Plan. The Doctor and the LP each
            acknowledges that the options granted and to be granted to the LP
            hereunder are being granted under and are subject to the Plan. All
            references to numbers of shares or price per share under this

<PAGE>
                                 [LOGO] DIOMED

      Agreement shall be subject to adjustment in a number of circumstances such
      as merger, consolidation, reorganization, recapitalization,
      reclassification, stock dividend, stock split, combination of shares,
      exchange of shares, change in corporate structure or the like, as provided
      in the Plan.

4.2   Investment Intent. The Doctor and the LP each agrees that the LP is
      acquiring and will acquire the Options and the shares of Common Stock
      issuable thereunder for its own account and not with a view to, or for
      sale in connection with, any "distribution" thereof within the meaning of
      the Securities Act of 1933, as amended (the "Securities Act").

4.3   Adequate Investigation. The Doctor and the LP each acknowledges that
      Diomed has granted him and it the opportunity to make a thorough
      investigation of the business affairs of Diomed and he and it has availed
      himself and itself of such opportunity, either directly or through his or
      its authorized representatives. In particular, Diomed has made available
      to the Doctor and the LP and their respective representative, access to
      Diomed officers and employees for the purpose of discussing and responding
      to questions concerning Diomed and its business and Diomed has furnished
      to the Doctor and the LP all agreements, financial statements and other
      documents pertaining to Diomed and its business requested by him or it.
      The Doctor and the LP each acknowledges that he and it has made an
      independent investigation of Diomed and an independent evaluation of the
      risks and merits of acquiring the Options and entering into this Agreement
      and has received all the information that he or it has requested in
      connection with deciding whether to accept the Options.

4.4   Investment Sophistication. The Doctor and the LP each acknowledges that he
      and it (a) is knowledgeable and experienced in business matters, (b) is
      capable of independently evaluating the risks and merits of accepting and
      exercising the Options granted hereunder, (c) has independently determined
      that the investment is a suitable investment for the LP, and (d) has
      sufficient financial resources to bear the loss of the LP's investment in
      the Options.

4.5   Restricted Securities. The Doctor and the LP each acknowledges and
      understands that, because neither the Options nor the Common Stock to be
      received upon exercise of the Options will be registered under the
      Securities Act or applicable state securities laws (even after Diomed
      becomes a public company), the LP will not be able to dispose of the
      Common Stock received upon exercise of the Options unless the sale of the
      shares of Common Stock received by it is registered or exemptions from
      such registration are available. The Doctor and the LP each further
      acknowledges and understands that neither he nor it has any right to
      require Diomed to register the Common Stock the LP receives upon exercise
      of any Options granted hereunder under the Securities Act or applicable
      state securities laws and that the Company may, as a condition to the
      transfer of Common Stock received upon exercise of the Options, require an
      opinion of counsel, in form and substance reasonably satisfactory to
      Diomed to the effect that the proposed transfer does not result in
      violation of the Securities Act or applicable state securities laws,
      unless such transfer is covered by an effective registration statement
      under the Securities Act and all applicable state securities laws. In
      furtherance of the above, each certificate representing shares of Common
      Stock received upon exercise of Options will bear a legend to that effect
      as well as any legend required by the Stockholder Agreement signed by the
      LP.

<PAGE>
                                 [LOGO] DIOMED

 4.6  Domicile. The legal domicile of each of the Doctor and the LP is Texas.

 4.7  Accredited Investor. The LP and the Doctor are an "accredited investor"
      within the meaning of Rule 501 of Regulation D promulgated under the
      Securities Act of 1933, as amended, and was not formed for the purpose of
      acquiring the Options.

5  Term and Termination

 5.1  Term. The Agreement shall be effective as of August 29, 2001 (the
      "Effective Date") and, unless earlier terminated as provided herein, shall
      automatically terminate on November 16, 2010 (the period from the
      Effective Date until expiration or earlier termination of this Agreement
      being referred to herein as the "Term").

 5.2  Termination by Diomed. This Agreement may be terminated in its entirety by
      Diomed effective upon the giving of notice of termination to the Doctor no
      later than January 31 following the end of any calendar year beginning
      with calendar year 2001 in which at least 50 Products are not sold
      worldwide for EVLT.

 5.3  Termination by the Doctor and the LP. This Agreement may be terminated by
      the Doctor (on behalf of himself and the LP) effective upon the giving of
      notice of termination to Diomed no later than January 31 following the end
      of any calendar year beginning with calendar year 2001 in which at least
      50 Products are not sold worldwide for EVLT. Also, this Agreement may be
      terminated by the Doctor (on behalf of himself and the LP) at any time
      after the second anniversary of the Effective Date effective upon the
      giving of six (6) months prior written notice of termination.

 5.4  Termination for Breach. Diomed, on the one hand, and the Doctor (on behalf
      of himself and the LP), on the other, may terminate this Agreement if the
      other defaults in the performance of any agreement, condition or covenant
      in this Agreement and this default is not remedied within sixty (60) days
      after written demand to remedy the same has been given to the other party.
      For purposes of this Section 5.4, failure by the Doctor to perform his
      agreed upon duties as set forth in Exhibit B shall constitute a breach of
      this Agreement. Upon termination for default, the non-defaulting party
      shall be free to pursue any and all remedies available to him or it. No
      remedy is intended to be exclusive and each remedy shall be cumulative.

 5.5  Termination upon Death or Discontinuation of Medical Practice of the
      Doctor. This Agreement shall terminate upon the death of the Doctor. Also,
      Diomed, on the one hand, and the Doctor (on behalf of himself and the LP),
      on the other, may terminate this Agreement if the practice of medicine
      ceases to be the Doctor's primary professional activity.

 5.6  Survival. Notwithstanding termination of this Agreement, Diomed's
      obligations under Sections 3.2, 3.3 and 3.6 shall survive with respect to
      Product sales for EVLT prior to the date of termination, and the
      obligations of the Doctor and the LP under Section 1.2 shall survive until
      November 16, 2010. Article IV, Section 6.2 and Sections 7.7 and 7.8 shall
      survive termination of this Agreement.

<PAGE>
                                 [LOGO] DIOMED

6    Representations, Warrants and Indemnification

     6.1   Authority and Enforcement. Each party to this Agreement warrants that
           he or it has full right, power and authority to enter into this
           Agreement and to perform the covenants and agreements contemplated
           hereby, that this Agreement has been duly executed and delivered by
           him or it and that the Agreement is enforceable against him or it in
           accordance with its terms, except as enforceability may be limited by
           bankruptcy, insolvency or other creditors' rights generally and the
           availability of equitable remedies, including specific performance.

     6.2   Limitation on Liability. EXCEPT AS SPECIFICALLY PROVIDED HEREIN AND
           IN ANY WARRANTY DELIVERED WITH THE PRODUCT, DIOMED GIVES NO
           WARRANTIES WHATSOEVER WITH RESPECT TO THE PRODUCT INCLUDING, BUT NOT
           LIMITED TO, ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A
           PARTICULAR PURPOSE. IN NO EVENT SHALL DIOMED ON THE ONE HAND OR THE
           DOCTOR AND/OR THE LP ON THE OTHER BE LIABLE TO THE OTHER FOR ANY
           INCIDENTAL, CONSEQUENTIAL OR SPECIAL DAMAGES THAT THE OTHER MAY
           SUFFER DIRECTLY OR INDIRECTLY AS A RESULT OF THE SALE OF THE PRODUCT
           FOR EVLT. NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED IN THIS
           AGREEMENT, IN NO EVENT SHALL THE TOTAL LIABILITY OF THE DOCTOR AND/OR
           THE LP FOR DAMAGES ARISING OUT OF THIS AGREEMENT EXCEED THE AGGREGATE
           AMOUNT OF CONSIDERATION RECEIVED BY THE DOCTOR AND/OR THE LP (WHETHER
           IN CASH, OR EXERCISED OPTIONS OR SHARES OF CAPITAL STOCK) UNDER THIS
           AGREEMENT

7    Miscellaneous

     7.1   Assignment. This Agreement shall be binding upon and inure to the
           benefit of the parties and to their respective successors, personal
           representatives, executors or assigns. Neither this Agreement nor any
           part of it shall be assignable by the Doctor or the LP to any third
           party. Diomed may assign this Agreement to a parent, subsidiary or
           other affiliate and to any party that acquires the EVLT business from
           Diomed, provided that such assignee assumes the obligations of Diomed
           hereunder in a written instrument delivered to the Doctor and the LP.

     7.2   Notices. Unless otherwise agreed in writing, all notices, requests
           and other communications pursuant to this Agreement shall be in
           writing and addressed as follows:

                           If to Diomed:

                                  Diomed, Inc.
                                  1 Dundee Park
                                  Andover, MA 01810
                                  Attn: Peter Klein

<PAGE>
                                 [LOGO] DIOMED

                      If to the Doctor or the LP:

                               Endovenous Associates, L.P.
                               1801 N. Lamar Blvd.
                               Austin, TX 78701
                               Attn: Steven E. Zimmet, M.D.

              Any notice or other communication under this Agreement shall be
              deemed to be sufficiently given if made in writing addressed as
              above and delivered (a) by hand or by recognized overnight
              delivery service, (b) by first class registered or certified mail,
              return receipt requested, or (c) by facsimile or electronic mail
              (with a confirmation copy dispatched as provided in subsection (a)
              or (b) above). Notice shall be deemed to have been given upon
              delivery if delivered under subsection (a) or (c) and at the
              expiration of five (5) business days after the date on which a
              notice is posted under subsection (b).

 7.3  Entire Agreement. This Agreement, together with the Exhibits attached
      hereto, represents the entire agreement between the parties with respect
      to the subject matter hereof and supersedes any other agreement or
      understanding, written or oral, that the parties heretofore may have had
      with respect thereto, including, without limitation, that certain Term
      Sheet dated as of December 18, 2000.

 7.4  Amendment. No amendment or other variation of this Agreement will be
      binding unless duly executed by an instrument in writing signed by the
      parties hereto.

 7.5  No Waiver. Failure by any party to enforce the performance of any of the
      provisions of this Agreement against another party shall neither
      constitute a waiver by it or him of its or his rights hereunder nor affect
      the validity of this Agreement in any way. Any waiver by a party hereto of
      a breach of this Agreement on the part of another party shall not
      constitute a precedent as to any subsequent breach on the part of such
      other party.

 7.6  Invalidity. In the event that any one or more of the provisions contained
      in this Agreement should be invalid, illegal or unenforceable in any
      respect, the validity, legality and enforceability of the remaining
      provisions contained herein shall not in any way be affected or impaired
      thereby.

7.7   Applicable Law. This Agreement shall be governed by the laws of the
      Commonwealth of Massachusetts without application of Massachusetts law
      with respect to conflicts of law.

7.8   Dispute Resolution. Any dispute that may arise between the parties in
      connection with or arising out of this Agreement must first be addressed
      by the President of Diomed and the Doctor who shall make a good faith
      effort to resolve the dispute. If, within thirty (30) days of written
      notice that a dispute exists there has been no resolution of the dispute,
      then such dispute shall be resolved exclusively by arbitration in
      accordance with the Commercial Arbitration Rules of the American
      Arbitration Association then in force. The arbitration shall take place in
      Boston, Massachusetts, or New York, New York, and shall be final and
      binding on the parties, shall not be subject to any appeal and shall
      address the question of costs of arbitration and the matters relating
      thereto. Judgment upon the

<PAGE>
                                 [LOGO] DIOMED

           award rendered may be entered in any court having jurisdiction, or
           application may be made to such court for a judicial recognition of
           the award or any order of enforcement thereof, as the case may be.

     7.9   Counterparts. This Agreement may be executed in one or more
           counterparts, each of which shall be deemed to be an original, but
           all of which shall be considered one and the same instrument.

    7.10   Headings. The headings in this Agreement are inserted for convenience
           only and shall not be used to interpret this Agreement or for any
           other purpose.

         IN WITNESS WHEREOF, the parties have executed this Agreement as of the
date first above written.

DIOMED, INC.

                                        /s/ STEVEN E. ZIMMET
                                        -------------------------
                                        DR. STEVEN E. ZIMMET

PETER KLEIN                             ENDOVENOUS ASSOCIATES, L.P.

Title: CEO

                                        By:_________________ Print Name:

                                        Title: Manager

                                       10

<PAGE>
                                 [LOGO] DIOMED

                                                                       EXHIBIT A

                  CERTIFICATION OF COMPLETION OF EVLT TRAINING

                            EVLT Training Certificate

                          This document certifies that Dr.

                             Street:
                             City:
                             ZIP, State:
                             Phone:
                             e-mail:

has successfully completed a one day training session on performing an EVLT
procedure.

The Training was performed by Dr.                     at the following location:

                    Street:
                    City:
                    ZIP, State:
                    Phone:
                    e-mail:

                       We thank you for your participation

 This certificate merely certifies that the above named physician has completed
 the training session described above, and does not certify that such physician
 possesses any particular level of skill, competency or experience with respect
                             to an EVLT procedure.

                                       11SEPARATION AGREEMENT DATED 9/30/2002

 Exhibit 10.1 
  
 September 30, 2002 
  
 Mr. Peter Steiner 
 xxxxx

 xxxxx 
  
 Re: Separation Agreement and Release 

 
 Dear Pete: 
  
 This letter confirms our recent conversations concerning your relinquishing your duties as Senior Vice President—Sales of Dice Inc. (f/k/a EarthWeb Inc.), and sets forth the agreement that has been reached between Dice Inc.,
including its subsidiaries, divisions, affiliates, predecessors, successors and assigns and its past and present officers, directors, shareholders, counsel, employees, agents, administrators, representatives, insurers or fiduciaries in their
individual and/or representative capacities (collectively referred to as the “Company”) and you regarding your separation from the Company, effective as of September 30, 2002 (the “Separation Date”). 
  

	1.
	 
	Effective on the Separation Date, your employment with the Company and your Employment Agreement, dated August 13, 2001, as amended, (the “Employment
Agreement”) are terminated. 
 

  

	2.
	 
	On the Separation Date, you will submit a written turnover report detailing the status of any projects planned or then in progress in which you are involved.

 

  

	3.
	 
	On the Separation Date, you will return all equipment, materials and records of the Company which are then in your possession and repay any advances from the
Company that may be then outstanding. Any expenses for which you are entitled to be reimbursed under the Company’s expense reimbursement policy will be reimbursed in accordance with the Company’s standard policies and procedures.

 

  

	4.
	 
	Provided that you abide by the terms of this Agreement and in consideration for the covenants and agreements herein contained: 
 

 

	 	(a)
	 
	The Company will continue to pay you your current base pay on a biweekly basis, less applicable withholding deductions, through the Separation Date. 

 

  

	 	(b)
	 
	On the Separation Date, the Company will pay you for your accrued but unused vacation days as of the Separation Date. 
 

 

	 	(c)
	 
	On the eighth day following the execution of this Agreement, the Company will pay you a lump sum severance payment equal to six months’ of your current
base pay, plus $5,000 for outplacement, legal expenses and other transitional items, less applicable withholding deductions  
 

  

	 	(d)
	 
	The Company will allow you to exercise any of your vested stock options at anytime prior to March 31, 2003. Vesting of your stock options will cease as of the
Separation Date. 
 

  

	 	(e)
	 
	The Company will provide you and your family with continuing health, dental and life insurance in the same manner as if you continued to be employed by the
Company through March 31, 2003. 
 

  

	5.
	 
	As a key executive of the Company, you have been intimately involved in the management of the business of the Company and in planning and implementing its
business strategies. In the course of your employment with the Company, you have developed special skills, knowledge and abilities in the online recruiting services field which are of a uniquely personal nature. You have also acquired
detailed knowledge of the internal operations of the Company and its business and possess highly confidential information concerning both the U.S. and non-U.S. business activities of the Company. In addition, you have been afforded the opportunity
to develop special relationships of confidence and trust with the customers, suppliers, consultants, employees, officers and directors of the Company. 
 

  

	6.
	 
	The parties acknowledge and agree that the Company would be unfairly and irreparably damaged if you were to take any of such skills, knowledge, information or
relationships, which you have acquired and developed during the course of your employment with the Company, and use them to the detriment of the Company, and therefore the provisions of this paragraph are reasonable, appropriate and necessary for
the protection of the Company’s properties, investments, business relationships, economic advantages and good will. Accordingly, you hereby agree that: 
 

  

	 	i.
	 
	For the period from the date of the Agreement through June 30, 2003, you will not, without the Company’s prior written consent, directly or indirectly hold
an ownership interest in, provide financing for, control, manage or operate, or participate in the ownership, control, management or operation of, or render services in the capacity of
 
 

 
an employee, freelancer, consultant, agent, independent sales representative or a similar capacity to or for the benefit of Monster/TMP, HotJobs, Yahoo Careers, CareerBuilder, HeadHunter,
Techies, ComputerJobs, Brass Ring, JustTechJobs, Computer Work, Brain Bench, Craig’s List, or Career Mag. Notwithstanding anything to the contrary contained herein, you shall not be deemed to have breached the provisions hereof solely by reason
of your ownership of an equity interest of less than one-half of one percent (0.5%) in the securities of a publicly traded competitive business or an interest in a mutual or other investment fund which owns an interest in one of the named entities,
provided that you have no influence or control over such fund’s investment decisions. 
  

	 	ii.
	 
	For the period from the date of the Agreement through June 30, 2003, you will not, without the Company’s prior written consent, on your own behalf or on
behalf of any other person or entity, (1) solicit the service of or employ any employee of the Company for your own benefit or the benefit of any person or entity other than the Company; (2) induce or help to induce any such employee to leave
employment with the Company for any reason; or (3) employ or cause any other person or entity to employ any former employee of the Company whose resignation from the Company occurred less than six months prior to such employment by you or such other
person or entity. You may seek a waiver of any provisions of this section in writing from the Company. 
 

  

	 	iii.
	 
	For the period from the date of the Agreement through June 30, 2003, you will not, without the Company’s prior written consent, (1) induce or attempt to
induce any customer, supplier or contractor of the Company to terminate or materially diminish any agreement or arrangement with the Company; or (2) induce or attempt to induce any customer, supplier or contractor, or any potential customer,
supplier or contractor of the Company not to enter into any agreement or arrangement with the Company. 
 

  

	 	iv.
	 
	You will not at any time, either during and after your employment, disclose, communicate or divulge, or use for your benefit or the benefit of any third party,
any of the trade secrets or other confidential or proprietary information and materials of the Company, including, solely by way of illustration but not of limitation, its business strategies, business plans, budgets, pricing, financial data,
confidential reports, personnel records, credit and financial data concerning its suppliers or its present and prospective customers, data about competitors, new product-development initiatives, customer research and new product or service ideas.
Once your employment has terminated, you will not retain copies of any confidential information or materials of the Company in any form, whether print, electronic or otherwise. 
 

  

	 	v.
	 
	You will not willfully make any oral or written statement which reflects adversely upon the character, honesty, credit, efficiency or business practices of the
Company or its former or current stockholders, directors, officers or employees in their capacities as such. 
 

  

	 	vi.
	 
	Both during and after your employment with the Company you will, if requested by the Company from time to time, provide information, testimony and assistance in
connection with the prosecution of any rights or claims by the Company and the defense of any claims against the Company arising out of matters of which you acquired knowledge while an employee of the Company. You agree to make yourself available
for such purpose at such times as the Company may reasonably request and as do not unreasonably interfere with your other business activities or commitments. The Company will pay any reasonable out-of-pocket expenses incurred by you in connection
with the foregoing (upon receipt of written documentation of such expenses). 
 

  

	 	vii.
	 
	You will not willfully take any action materially adverse to the interests of the Company, even if such action is in technical compliance with the other
provisions of this letter, but shall at all times conduct yourself in the same manner and with the same degree of loyalty to the Company as if you were still an employee and officer of the Company. 
 

  

	 	viii.
	 
	You will keep this letter strictly confidential and, except as may be required by law, you agree not to disclose it or any of its terms or conditions to any
person other than your legal counsel and financial advisors to whom disclosure is necessary to effectuate the purposes of your consulting with such advisors, provided that they are informed of the confidentiality agreement herein and agree to be
bound by it. For purposes of the restrictions in this agreement that relate to non-competition and non-solicitation, you may provide a summary description or excepts of those provisions of the agreement to a prospective employer, provided it is
informed of the confidentiality agreement herein and agrees to be bound by it. In the event that any court or agency of competent jurisdiction shall require this Agreement to be filed with it, you and the Company shall request that the Agreement be
filed and maintained under seal. 
 

  

	7.
	 
	You hereby fully release and discharge the Company and its successors and assigns from any and all claims, liabilities, obligations, damages, losses, costs and
expenses, known and unknown, suspected or unsuspected, which you have, have had or may hereafter have arising out of your employment with the Company, the termination thereof or your compensation in connection therewith (other than obligations
created by, acknowledged in or arising from this agreement), and you hereby waive any and all rights to assert against the Company and its successors and assigns, any such claims, including, without limitation, claims of discrimination (whether
based on race, religion, national origin, sex, sexual orientation, age, marital status, veteran status, handicap, physical or mental disability, or any other cause), wrongful discharge, emotional distress, defamation, breach of contract, breach of
covenant of good faith and fair dealing, claims for wages, bonuses, vacation or sick pay or other benefits, and violation of any local, state or 
 

  

 federal law or regulation. You specifically waive any and all rights and claims arising under the federal Age
Discrimination in Employment Act of 1967 (although such waiver does not apply to rights or claims that may arise after the date this Agreement is executed). 
  

	9.
	 
	You acknowledge and agree that, except as expressly provided herein, you will be entitled to no further employment with the Company, and, except for the
foregoing, you are not entitled to and will not receive any additional compensation, payments or benefits of any kind from the Company, and that no representations or promises to the contrary have been made to you. 
 

 

	10.
	 
	This letter sets forth our entire agreement with respect to the subject matter thereof and supersedes all prior written or oral agreements between you and any
representative of the Company on that subject including without limitation the Employment Agreement dated as of August 13, 2001, between the Company and you, as amended from time to time. No provision of this agreement may be modified or waived
except in a writing signed by the party against whom the enforcement of any such modification or waiver is sought. If any provision of this agreement is prohibited or invalid under any law, such provision shall be ineffective to the extent of any
prohibition or invalidity, without invalidating the remainder of such provision or the other provisions of this agreement. This agreement will bind and benefit both parties and their respective heirs, executors, administrators, successors and
assigns. This agreement shall be governed by and construed in accordance with the laws of the State of New York without reference to its rules regarding choice or conflicts of laws. 
 

  

	11.
	 
	You acknowledge that you have had a reasonable amount of time and an opportunity to review this agreement and have been afforded the opportunity to review its
terms with an attorney prior to execution. You acknowledge that you have read and understand this agreement; that you have signed it voluntarily and without coercion; and that the waivers you have made in this agreement have been made with full
appreciation that you will be foreclosed from pursuing the rights so waived. You agree that if you assert or attempt to assert any claims or rights so waived, you will pay all costs incurred by the Company or its employees, including reasonable
attorneys’ fees and disbursements, in defending against such claims. 
 

  

	12.
	 
	You are advised to consult with an attorney prior to executing this agreement. You have 45 days from the date of this letter to consider this agreement. For a
period of seven (7) days following the execution of this agreement, you may revoke the agreement by delivering written notice of revocation to the Company’s Vice President & General Counsel at 3 Park Avenue, New York, NY 10016. This
agreement will not become effective or enforceable until the 7-day revocation period has expired. If the 7-day revocation period expires without you having revoked the agreement, the agreement becomes effective as of the date executed by both
parties. If you revoke the agreement, the Company will not be bound by the terms set forth above. You understand that your acceptance of any of the payments or benefits described herein at any time after you sign this agreement and release confirms
that you did not revoke your consent to this agreement and release and therefore that it is fully effective and enforceable. 
 

  
 If the above accurately reflects our agreement on this matter, please sign the attached duplicate of this letter in the space provided below and return it to me. 
  
 
	 
	 Sincerely,
 	  	  
	 
	 DICE INC.
 	  	  
	 
	 By:    /s/    SCOT W.
MELLAND                
 
	  	 October 17, 2002
 

	 Scot W. Melland
 Chairman,
President & CEO
 	  	 Date
 
	 
	 AGREED AND ACCEPTED:
 	  	  
	 
	 /s/    PETER
STEINER        
 
	  	 October 18, 2002
 

	 Peter Steiner
 	  	 Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00044-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00044-of-00352.parquet"}]]